Epinephrine is the first-line treatment for severe allergic reactions, but far too often, people do not use or get it when needed.

The FDA’s recent approval of neffy®, an epinephrine nasal spray, is a huge breakthrough. The allergy community now has a treatment option for severe and potentially life-threatening allergic reactions that does not use a needle.

“An epinephrine nasal spray like neffy offers a new treatment option for people with anaphylaxis," said Kenneth Mendez, President and CEO of AAFA. "Our research suggests fear of needles is a top reason people are reluctant to use epinephrine auto-injectors. An option without a needle could mean epinephrine is more widely carried and used, making the first-line treatment for anaphylaxis more widely available."

This exciting milestone shows that change can happen when we come together. As your health ally, we’ve listened to your challenges and advocated for new treatment options to help you manage allergies without fear.

Last spring, our Chief Mission Officer, Melanie Carver, shared insights from our community with the FDA about the daily struggles of managing food allergies and the need for more treatment options. Today, we applaud progress.

Read the FDA press release to learn more about neffy and see our answers to common questions about neffy.